MGD019 DART® Protein in Unresectable/Metastatic Cancer



Status:Recruiting
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/13/2019
Start Date:December 12, 2018
End Date:December 2023
Contact:Kerri Cali
Email:calik@macrogenics.com
Phone:240.552.8666

Use our guide to learn which trials are right for you!

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK)
pharmacodynamics and preliminary antitumor activity of MGD019.

This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and
maximum tolerated/administered dose (MTD/MAD) of MGD019. Dose escalation will occur in a
3+3+3 design in patients with advanced solid tumors of any histology. Once the MTD/MAD is
determined, a Cohort Expansion Phase will be enrolled to further characterize safety and
initial anti-tumor activity in patients with specific tumor types anticipated to be sensitive
to dual checkpoint blockade.

Inclusion Criteria:

- Dose escalation: Patients with histologically proven, unresectable, locally advanced
or metastatic solid tumors for whom no approved therapy with demonstrated clinical
benefit is available or patients who are intolerant to standard therapy.

- Cohort Expansion Phase: Disease-specific prior therapy requirements to be specified.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

- Life expectancy ≥ 12 weeks.

- Measurable disease as per RECIST 1.1 for the purpose of response assessment must
either (a) not reside in a field that has been subjected to prior radiotherapy or (b)
have demonstrated clear evidence of radiographic progression since the completion of
prior radiotherapy and prior to study enrollment.

- All patients must have an identified formalin-fixed, paraffin embedded (FFPE) tumor
specimen (up to 20 slides or a block) for immunohistochemical evaluation of
pharmacodynamic markers of interest.

- Acceptable laboratory parameters and adequate organ reserve.

Exclusion Criteria:

- In patients who have previously received an immune checkpoint inhibitor (e.g.,
anti-PD-L1, anti-PD-1, anti-CTLA-4), toxicities related to the checkpoint inhibitor
must have resolved to ≤ Grade 1 or baseline. Patients with well controlled immune
endocrinopathies secondary to prior checkpoint therapy are eligible.

- Patients with symptomatic CNS metastases. Patients with history of prior CNS
metastasis must have been treated, must be asymptomatic, and must not have concurrent
treatment for the CNS disease, progression of CNS metastases on magnetic resonance
imaging (MRI) or computed tomography (CT) for at least 14 days after last day of prior
therapy for the CNS metastases, or concurrent leptomeningeal disease or cord
compression.

- Patients who sustained the following Grade 3 immune checkpoint inhibitor related AEs
are ineligible: Ocular AE, changes in liver function tests that met the criteria for
Hy's law (> 3 × ULN of either ALT or AST with concurrent > 2 × ULN of total bilirubin
and without alternate etiology), neurologic toxicity, colitis, renal toxicity,
pneumonitis.

- Patients who have received prior therapy with a combination of monoclonal antibodies
against PD-1/PD-L1 and CTLA-4 will be excluded in the Cohort Expansion.

- Patients with any history of known or suspected autoimmune disease with certain
exceptions

- History of prior allogeneic bone marrow, stem-cell, or solid organ transplantation.

- History of trauma, major surgical procedure, systemic antineoplastic therapy, or
investigational therapy within the 4 weeks prior to initiation of study drug
administration.

- Treatment with radiation therapy within 2 weeks prior to initiation of study drug
administration.
We found this trial at
4
sites
Nashville, Tennessee 37203
Principal Investigator: Johanna Bendell, MD
Phone: 615-329-6875
?
mi
from
Nashville, TN
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Rachel Sanborn, MD
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
(773) 702-1000
Principal Investigator: Jason Luke, MD
Phone: 773-702-1227
University of Chicago Medical Center The University of Chicago Medicine has been at the forefront...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Principal Investigator: Manish Sharma, MD
Phone: 616-389-1739
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials